With incomes under $150,000 OR INSURED PATIENTS WITH COVERAGEfor a Genentech medicine† • With unaffordable out-of-pocket costs • With household size and income within the guidelines listed below HOUSEHOLD SIZE ANNUAL INCOME Less than $75,000 Less than $100,000 Less than $125,000 Less than $150,000
Do I qualify for support from the Genentech patient Foundation?
If one of these situations applies to you, you may qualify for support from the Genentech Patient Foundation. Please complete the enrollment forms to apply for help. If one of these situations does not apply to you, help may still be available. Genentech Access Solutions can help you understand insurance coverage and other assistance options.
How can I get Free Genentech medicine?
‡ To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements.
How do I contact Genentech for more information about Actemra® supply?
For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here. Genentech Patient Foundation
See more
What is the Genentech Patient Foundation?
The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns.
What is Genentech access solutions?
Access Solutions is a program from Genentech and is committed to helping you understand your insurance coverage and options that might be able to help you pay for your Genentech medicine. Call (866) 422-2377 or visit Genentech-Access.com for more information.
Is Tecentriq covered by insurance?
To be eligible for free TECENTRIQ from the Genentech Patient Foundation, insured patients who have coverage for their medicine must have exhausted all other forms of patient assistance (including the Genentech Oncology Co-pay Program and support from independent co-pay assistance foundations) and must meet certain ...
What drugs does Genentech make?
Our Medicines & ProductsMedicines.Actemra® (TOCILIZUMAB [authorized for Emergency Use])Actemra® (tocilizumab)Activase® (alteplase)Alecensa® (alectinib)Avastin® (bevacizumab)Boniva Tablets® (ibandronate sodium)Cathflo Activase® (alteplase)More items...
What is Ophthalmology access solutions?
We focus on access so you can focus on health Genentech Ophthalmology Access Solutions is a program that helps people who are taking a Genentech medicine. Your health insurance plan and the cost of your medicine might keep you from getting your prescribed treatment.
Who makes Valganciclovir?
Genentech: Valcyte® (valganciclovir hydrochloride) - Information for Patients.
What is J9022 used for?
HCPCS code J9022 for Injection, atezolizumab, 10 mg as maintained by CMS falls under Chemotherapy Drugs.
Does Pfizer own Genentech?
Roche Holding's agreement on Thursday to acquire full ownership of Genentech for $46.8 billion is the third big drug industry merger this year. But it is different from the other two — Pfizer's $68 billion proposal to acquire Wyeth and Merck's $41 billion deal with Schering-Plough — in crucial ways.
What is Genentech best known for?
Genentech is a biotechnology company dedicated to pursuing groundbreaking science to discover and develop medicines for people with serious and life-threatening diseases. Our transformational discoveries include the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis.
Where do Genentech employees live?
South San FranciscoWorking and living in South San Francisco, these employees are proud members of a thriving community.
How much is Atezolizumab?
Official answer. Tecentriq treatment costs around $14,540 per month depending on the dosage schedule. Tecentriq (atezolizumab) is a programmed death-ligand 1 (PD-L1) blocking antibody (or immune checkpoint inhibitor) used in the treatment of: urothelial carcinoma.
What is the CPT code for Tecentriq?
Effective January 1, 2018, the permanent J-code is J9022 (injection, atezolizumab, 10 mg). TECENTRIQ®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc. CPT=Current Procedural Terminology. NDC=National Drug Code.
Is Tecentriq an immunotherapy?
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC). It's the second immunotherapy drug approved for people with advanced SCLC, but the first approved for use as part of the initial (first-line) treatment.
What are the side effects of Tecentriq?
The most common side effects of TECENTRIQ when used in melanoma with cobimetinib and vemurafenib include:skin rash.joint, muscle, or bone pain.feeling tired or weak.liver injury.fever.nausea.itching.swelling of legs or arms.More items...
How to enroll in Genentech?
Fill out the program enrollment form located to your right. If you don't see an enrollment form available please call Genentech, Inc. program directly. After filling out the enrollment form please bring the form to your doctor for proper signatures and procedures. Do not forget a self stamped envelope for them to mail in your application to the program.
Does Genentech have Xolair?
Genentech Access to Care Foundation (Xolair), a patient assistance program provided by Genentech, Inc., offers Xolair at no cost for up to 1 year to those who are eligible for the program. Eligibility is based off of the following requirements:
Summary
Genentech, Inc. was founded in 1976 by Robert A. Swanson and Dr. Herbert W. Boyer. The company is primarily based around the field of recombinant DNA technology that was founded by Boyer and colleague Stanley Cohen. Over their 30+ year history, Genentech, Inc.
Eligibility
Genentech Access to Care Foundation (Raptiva), a patient assistance program provided by Genentech, Inc., offers Raptiva at no cost for up to 1 year to those who are eligible for the program. Eligibility is based off of the following requirements:
Other Tips
If you have any questions please call the Genentech, Inc. program directly.